Lynparza granted FDA Priority Review for PAOLA-1
13 January 2020 07:00 GMT Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer Submission based on Phase III PAOLA-1 trial for patients with advancedovarian cancer regardless of biomarker status or surgical outcome AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab has been accepted and granted Priority Review